CINCINNATI, April 12, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced the signing of a Sponsored Research Agreement (the “Agreement”) with The University of Texas Health Science Center at San Antonio (“UT Health Science Center San Antonio”) to fund a non-human primate (“NHP”) study to evaluate the efficacy of BWV-401, a live attenuated, orally delivered Chlamydia vaccine.

Read more here:
Blue Water Vaccines Announces Signing of Sponsored Research Agreement with The University of Texas Health Science Center at San Antonio to Initiate...

– Lalo Flores, Ph.D., steps down as Chief Executive Officer and member of Board of Directors; Greg Russotti, Ph.D., Chief Technology Officer, assumes role of ad-interim Chief Executive Officer –

Read the original post:
Century Therapeutics Announces Leadership Changes

Company’s SAB is comprised of well-established leaders with expertise across biomedical research, academia, and pharmaceutical industry

Read the original:
AIM ImmunoTech Appoints Preeminent Biotechnology Pioneer, W. Neal Burnette, Ph.D., as Chairman of its Scientific Advisory Board (SAB)

CHAPEL HILL, N.C., April 12, 2023 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today provided a business update outlining the Company’s product development plans for 2023.

Visit link:
Tenax Therapeutics Provides 2023 Business Update

– 2022 marks Ceapro’s best performance in Company history with record sales of $18,800,000 compared to $17,200,000 for 2021, representing a 10% increase year over year

Link:
Ceapro Inc. Reports Record 2022 Financial Results and Operational Highlights

Press release – No. 2 / 2023

See the rest here:
Zealand Pharma to Participate in 22nd Annual Needham Virtual Healthcare Conference

Dr. Satiro De Oliveira, a principal investigator in the Company’s cancer research program at UCLA, comments about the importance of cancer immunotherapy Dr. Satiro De Oliveira, a principal investigator in the Company’s cancer research program at UCLA, comments about the importance of cancer immunotherapy

See more here:
CancerVAX CEO Ryan Davies Discusses Cancer Research with Leading Pediatric Hematologic Oncologist

Hariri, Celularity’s CEO, Chairman and Founder, will open the meeting with the keynote address highlighting recent progress and important next steps for the science of longevity together with Scott Gottlieb, M.D., Senior Fellow of the American Enterprise Institute and former Commissioner of the U.S. Food and Drug Administration

More:
Celularity’s Dr. Robert Hariri To Co-Chair The 2023 International Precision Medicine Center (IPMC) Conference “Beyond Longevity: Live 120 Like...

Read this article:
AB Science: Results of masitinib in ALS selected for a scientific platform presentation at the AAN 2023, including long-term survival analysis and a...

YARDLEY, Pa., April 12, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the Needham Virtual Healthcare Conference on April 17, 2023 at 3:45 p.m. ET.

More:
Optinose to Present at the Needham Virtual Healthcare Conference

Monthly information related to total number of voting rights and shares composing the share capital _March 31, 2023.

Read the original post:
 Monthly information related to total number of voting rights and shares composing the share capital _March 31, 2023

H. Stewart Parker Departing from Board H. Stewart Parker Departing from Board

See the rest here:
Impel Pharmaceuticals Announces Appointment of Darren Cline to the Board of Directors

Management to host investor conference call and webcast at 4:30pm EDT on that day Management to host investor conference call and webcast at 4:30pm EDT on that day

View original post here:
MedAvail to Report Fourth Quarter and Full Year 2022 Financial Results on April 13

CAMBRIDGE, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the 22nd Annual Needham Virtual Healthcare Conference to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Scott Barrett, M.D., Chief Medical Officer, Brett Hall, Ph.D., Chief Scientific Officer, and Mallory Morales, CPA, Vice President of Finance, Treasurer.

Read the original here:
Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference

Board of Directors unanimously recommend Vallon stockholders to vote “FOR” all proposals outlined in the Company’s definitive Proxy Statement (the “Proxy”) in order to close the proposed merger with GRI Bio, Inc.

Excerpt from:
Vallon Pharmaceuticals Adjourns Special Meeting of Stockholders Until April 20, 2023

Hypoimmune human islet cells normalized glucose in diabetic humanized immunocompetent mouse model and avoided allogeneic and autoimmune rejection by the immune system

Excerpt from:
Sana Biotechnology Announces Preclinical Data Published in Science Translational Medicine Showing its Hypoimmune Pancreatic Islet Cells Evaded...

Spinach® rose to 8th place in the pre-roll category, capturing 2.5% market share in Q1 2023, up from 1.4% in Q4 20221

More:
Cronos Bolsters its Spinach® Infused Pre-roll Portfolio with CBG, CBC and CBN

Montrouge, France, April 12, 2023

Link:
DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting

Three posters support the important role that XPHOZAH, a novel phosphate absorption inhibitor, could potentially play in the treatment of hyperphosphatemia

Go here to see the original:
Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2023 Spring Clinical...

SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at two upcoming investor conferences:

Continue reading here:
Nkarta to Participate at Upcoming Investor Conferences